tiprankstipranks
Trending News
More News >
Haleon PLC (GB:HLN)
LSE:HLN

Haleon PLC (HLN) AI Stock Analysis

Compare
249 Followers

Top Page

GB

Haleon PLC

(LSE:HLN)

Rating:67Neutral
Price Target:
417.00p
▲(11.95%Upside)
Haleon PLC's overall stock score reflects strong financial performance and positive earnings call outlook. Despite some bearish technical indicators and valuation concerns, the company's strategic initiatives in growth markets and its commitment to shareholder returns provide a positive long-term outlook. Challenges such as market headwinds and inventory adjustments are notable risks.
Positive Factors
Financial Outlook
Analysts forecast a 2026-30 EPS compound annual growth rate of 8.4%, which is ahead of its Household and Personal Care peers.
Market Position
Haleon's resilient categories and market share gains are expected to result in continued outperformance relative to peers.
Operational Efficiency
Gross savings of £800 million in supply chain are expected over five years to enhance gross margin improvement.
Negative Factors
Consumer Sentiment
Potential risks include significant deceleration in US and/or European consumer sentiment, impacting Haleon's categories and resulting in EPS downside.
Market Valuation
The stock is trading at a 20% premium to peers, which limits further upside unless there is a clearer path to higher growth.

Haleon PLC (HLN) vs. iShares MSCI United Kingdom ETF (EWC)

Haleon PLC Business Overview & Revenue Model

Company DescriptionHaleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
How the Company Makes MoneyHaleon PLC generates revenue primarily through the sale of its consumer healthcare products across various global markets. The company’s revenue streams are diversified across its core product categories, with significant contributions from brands that hold leading market positions in their respective segments. Haleon benefits from strong distribution channels, both through direct sales to retailers and partnerships with healthcare professionals and pharmacies. Additionally, the company invests in research and development to innovate and enhance its product offerings, thereby driving consumer demand and market share growth. Strategic partnerships and marketing initiatives further strengthen its revenue generation capabilities by expanding its reach and enhancing brand recognition.

Haleon PLC Earnings Call Summary

Earnings Call Date:Feb 27, 2025
(Q4-2024)
|
% Change Since: -4.66%|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strong performance in emerging markets and the Oral Health segment, driven by innovation and strategic investments. However, challenges such as a weak cold and flu season, disappointing Eroxon launch, and currency headwinds were notable concerns. Despite these issues, the company remains confident in its growth outlook and has committed to returning capital to shareholders.
Q4-2024 Updates
Positive Updates
Strong Performance in Emerging Markets
Significant momentum observed in emerging markets, especially in India and China, contributing to growth expectations for the second half of 2025.
Oral Health Segment Expansion
Successful performance in Oral Health with notable products like Clinical White, planned expansion into 12 more markets, and new launches such as clinical enamel repair in the US.
Innovation Driving Growth
Innovation is a key driver across all categories, with new products like Otrivin Nasal Mist and Centrum Essentials contributing to share gains and category growth.
Increased Investment in Growth
Continued focus on investing in growth with a 10.2% increase in A&P investment, indicating confidence in business fundamentals.
Capital Return to Shareholders
Announcement of a £500 million share buyback and increased dividend, reflecting strong cash flow confidence.
Negative Updates
Impact of Weak Cold and Flu Season
A low cold and flu season led to a 15% decline in the respiratory health category in both the US and globally, affecting inventory levels.
Disappointing Eroxon Launch
The launch of Eroxon did not meet expectations, with slower-than-expected early trial results.
Currency Headwinds
Ongoing FX headwinds are expected to impact revenue and profit, particularly in the first half of 2025.
Challenges in US Retail Environment
Some US retailers, particularly in the drug channel, are struggling with inventory levels, affecting cash management.
Company Guidance
During the call, Haleon provided guidance for 2025, indicating a projected growth of 4% to 6%, despite a slow start due to factors like a 15% decline in the cold and flu market and inventory adjustments. The company expressed confidence in its performance, highlighting that 71% of its business maintained or gained market share in 2024. Key growth drivers include strong momentum in emerging markets like India and China, robust performance in the Oral Health segment, and ongoing innovation across categories, such as Otrivin Nasal Mist and Centrum Silver. The company also mentioned a £500 million share buyback and maintained capacity for bolt-on M&A, despite ongoing currency headwinds of 1% to 2.5% on revenue and margin. Haleon's strategic focus remains on innovation, expanding market reach, and optimizing operational efficiency.

Haleon PLC Financial Statement Overview

Summary
Haleon PLC shows strong financial performance with a solid income statement, stable balance sheet, and robust cash flow generation. Despite minor setbacks in revenue growth, profitability and cash flow metrics remain strong.
Income Statement
78
Positive
Haleon PLC demonstrates solid profitability with gross profit margins consistently around 60% over the years. Net income has shown resilience with a significant increase from 2022 to 2024. The company has also managed steady revenue growth, although there was a slight decline in revenue from 2023 to 2024. EBIT and EBITDA margins remain strong, indicating effective cost management.
Balance Sheet
70
Positive
The balance sheet of Haleon PLC shows a balanced equity position with a stable stockholders' equity. The debt-to-equity ratio is moderate, reflecting a manageable level of debt compared to equity. The equity ratio indicates a solid capital structure, though the total liabilities have increased over the years, suggesting a need for cautious debt management.
Cash Flow
82
Very Positive
The company has demonstrated strong cash flow management, with operating cash flow consistently exceeding net income, indicating healthy cash generation from operations. Free cash flow has been growing steadily, showing robust capability for reinvestment and debt servicing. The free cash flow to net income ratio highlights efficient conversion of earnings into cash.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue11.26B11.23B11.30B10.86B9.54B9.89B
Gross Profit6.83B6.82B6.75B6.58B5.95B5.91B
EBITDA2.11B2.63B2.36B2.19B2.21B1.92B
Net Income1.09B1.44B1.05B1.06B1.39B1.15B
Balance Sheet
Total Assets33.40B34.31B34.05B34.81B34.45B34.13B
Cash, Cash Equivalents and Short-Term Investments531.00M2.19B1.04B684.00M414.00M334.00M
Total Debt8.86B10.10B9.46B10.44B991.00M487.00M
Total Liabilities16.69B18.09B17.33B18.36B7.97B7.91B
Stockholders Equity16.60B16.17B16.61B16.33B26.36B26.11B
Cash Flow
Free Cash Flow0.001.98B1.76B1.74B1.06B1.09B
Operating Cash Flow0.002.30B2.10B2.06B1.36B1.41B
Investing Cash Flow0.00528.00M-134.00M-8.78B-33.00M1.03B
Financing Cash Flow0.00-1.54B-1.57B6.91B-1.24B-2.44B

Haleon PLC Technical Analysis

Technical Analysis Sentiment
Negative
Last Price372.50
Price Trends
50DMA
394.24
Negative
100DMA
388.90
Negative
200DMA
380.78
Negative
Market Momentum
MACD
-6.73
Positive
RSI
29.94
Positive
STOCH
17.71
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:HLN, the sentiment is Negative. The current price of 372.5 is below the 20-day moving average (MA) of 386.18, below the 50-day MA of 394.24, and below the 200-day MA of 380.78, indicating a bearish trend. The MACD of -6.73 indicates Positive momentum. The RSI at 29.94 is Positive, neither overbought nor oversold. The STOCH value of 17.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:HLN.

Haleon PLC Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
81
Outperform
£202.83M5.5833.70%1.52%-0.17%2591.96%
GBHIK
79
Outperform
£4.39B15.6915.79%2.90%5.83%83.35%
GBHLN
67
Neutral
£33.74B23.798.80%1.83%-0.61%39.00%
GBAPH
59
Neutral
$355.92M-5.04%-1.02%67.70%
GBAGY
53
Neutral
£381.32M-369.20%4.50%74.32%
50
Neutral
kr5.37B12.51-80.61%5.13%37.36%27.71%
GBBXP
$38.41B3.6413.12%9.57%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:HLN
Haleon PLC
373.10
56.50
17.85%
GB:AGY
Allergy Therapeutics
8.00
3.20
66.67%
GB:APH
Alliance Pharma
64.70
27.20
72.53%
GB:ANCR
Animalcare
294.00
64.47
28.09%
GB:HIK
Hikma Pharmaceuticals
1,986.00
209.02
11.76%
GB:BXP
Beximco Pharmaceuticals Limited Sponsored GDR RegS
35.00
-1.04
-2.89%

Haleon PLC Corporate Events

Executive/Board Changes
Haleon PLC Announces Vesting of Share Awards to CFO
Neutral
Jul 2, 2025

Haleon PLC announced the vesting of share awards to its Chief Financial Officer, Dawn Allen, under the company’s Share Value Plan and Performance Share Plan. These awards were part of her remuneration package to compensate for incentives forfeited from her previous employment. The vesting includes dividends and is subject to conditions such as continued employment and performance metrics. The shares are also subject to malus and clawback provisions, ensuring alignment with company performance and governance standards.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Regulatory Filings and Compliance
Haleon PLC Updates Total Voting Rights and Share Capital
Neutral
Jul 1, 2025

Haleon PLC announced that as of June 30, 2025, it has issued a total of 8,988,533,553 ordinary shares, with 3,880,205 held as treasury shares. This results in 8,984,653,348 shares having voting rights, a key figure for shareholders and stakeholders to determine their notification obligations under the FCA’s Disclosure Guidance and Transparency Rules. This update is crucial for maintaining transparency and ensuring stakeholders are informed about their voting rights and obligations.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock Buyback
Haleon PLC Advances Share Buyback Program with Significant Share Purchase
Positive
Jun 24, 2025

Haleon PLC announced the purchase and cancellation of over one million ordinary shares as part of its ongoing share buyback program. This transaction reflects the company’s commitment to optimizing its capital structure and enhancing shareholder value, potentially impacting its market positioning and signaling confidence in its financial health.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Positive
Jun 23, 2025

Haleon PLC announced a share buyback transaction, purchasing 1,016,186 ordinary shares for cancellation under its buyback program. This move is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value by reducing the number of shares in circulation, which may impact voting rights and shareholding notifications under regulatory rules.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Enhance Shareholder Value
Positive
Jun 20, 2025

Haleon PLC announced the purchase and cancellation of 1,011,111 ordinary shares as part of its share buyback program, which was initiated on March 28, 2025. This transaction reflects Haleon’s strategic financial management, potentially enhancing shareholder value by reducing the number of shares in circulation. The company’s registered share capital now stands at 8,992,573,595 ordinary shares, with 8,988,493,390 shares holding voting rights, which may affect shareholder notifications under regulatory guidelines.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock Buyback
Haleon PLC Advances Share Buyback Program with Recent Share Purchase
Positive
Jun 20, 2025

Haleon PLC announced the purchase and cancellation of over one million ordinary shares as part of its ongoing share buyback program. This move is expected to optimize the company’s capital structure and potentially enhance shareholder value by reducing the number of shares in circulation, thereby increasing the value of remaining shares.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock Buyback
Haleon PLC Executes Share Buyback to Adjust Capital Structure
Neutral
Jun 19, 2025

Haleon PLC has announced the purchase and cancellation of over one million of its own shares as part of a share buyback program initiated in March 2025. This move is likely to impact the company’s share capital structure, reducing the number of shares with voting rights, which may influence shareholder notifications under regulatory guidelines.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Positive
Jun 18, 2025

Haleon PLC announced a share buyback transaction, purchasing 991,883 ordinary shares for cancellation as part of its ongoing buyback program. This move reflects the company’s strategy to manage its capital structure and potentially enhance shareholder value, impacting the number of shares with voting rights to 8,990,513,705.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

DividendsRegulatory Filings and Compliance
Haleon PLC Announces Director Shareholding Transaction
Neutral
Jun 17, 2025

Haleon PLC announced a transaction involving a Person Discharging Managerial Responsibilities, Marie-Anne Aymerich, who acquired ordinary shares through dividend reinvestment. This transaction, conducted on the London Stock Exchange, reflects the company’s adherence to UK Market Abuse Regulation requirements and highlights its ongoing commitment to transparency and regulatory compliance.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock Buyback
Haleon PLC Executes Share Buyback, Adjusts Share Capital
Neutral
Jun 16, 2025

Haleon PLC announced the purchase and cancellation of 966,880 ordinary shares as part of its share buyback program. This transaction affects the company’s share capital, reducing the number of shares with voting rights to 8,992,482,913, which stakeholders can use to assess their interests under regulatory guidelines.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Advances Share Buyback Program with Recent Share Repurchase
Positive
Jun 13, 2025

Haleon PLC has announced the repurchase of 971,129 ordinary shares as part of its ongoing share buyback program, initially announced in March 2025. This transaction reflects the company’s strategic focus on optimizing its capital structure and enhancing shareholder value, with the current registered share capital standing at nearly 9 billion ordinary shares.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Enhance Financial Strategy
Neutral
Jun 12, 2025

Haleon PLC announced a share buyback transaction involving the purchase and cancellation of 974,260 ordinary shares as part of its ongoing buyback program. This action, which adjusts the company’s share capital and voting rights, reflects Haleon’s strategic financial management and could influence shareholder interests and market perceptions.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Regulatory Filings and Compliance
Haleon PLC Discloses PDMR Share Transactions
Neutral
Jun 11, 2025

Haleon PLC, a company listed on the London Stock Exchange and New York Stock Exchange, has disclosed transactions by its Persons Discharging Managerial Responsibilities (PDMRs) in accordance with the UK Market Abuse Regulation. The transactions involved the sale and acquisition of ordinary shares by key executives, including Keith Choy, Alan Stewart, Dawn Allen, and Filippo Lanzi, with transactions taking place on the London Stock Exchange. These transactions highlight the ongoing financial activities and shareholding changes within the company’s leadership, potentially impacting investor perceptions and market dynamics.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Positive
Jun 11, 2025

Haleon PLC announced the purchase of 972,579 ordinary shares for cancellation as part of its share buyback program. This transaction, which involved shares priced between 395.20p and 399.20p, reflects the company’s ongoing efforts to manage its capital structure effectively. Following this purchase, Haleon’s registered share capital stands at 8,999,475,387 ordinary shares, with 8,995,395,182 shares holding voting rights. This move is part of Haleon’s strategic initiatives to enhance shareholder value and optimize its financial operations.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Positive
Jun 10, 2025

Haleon PLC announced a share buyback transaction involving the purchase and cancellation of 817,635 ordinary shares as part of its ongoing buyback program. This move is part of Haleon’s strategy to optimize its capital structure and potentially enhance shareholder value by reducing the number of shares in circulation, which may impact the company’s market positioning and stakeholder interests.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackRegulatory Filings and Compliance
Haleon PLC Executes Share Buyback to Adjust Capital Structure
Neutral
Jun 9, 2025

Haleon PLC announced the purchase and cancellation of 827,966 ordinary shares as part of its share buyback program initiated in March 2025. This move adjusts the company’s share capital and voting rights, potentially impacting shareholder interests and aligning with regulatory transparency requirements.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackRegulatory Filings and Compliance
Haleon PLC Executes Share Buyback, Adjusts Share Capital
Neutral
Jun 5, 2025

Haleon PLC has announced the purchase and cancellation of 815,673 ordinary shares as part of its share buyback programme initiated in March 2025. This transaction impacts the company’s share capital, reducing the number of shares with voting rights, which may influence shareholder notifications under regulatory guidelines.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and StrategyRegulatory Filings and Compliance
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Positive
Jun 4, 2025

Haleon PLC announced the purchase and cancellation of 794,956 ordinary shares as part of its ongoing share buyback program. This move is part of a strategic effort to manage its capital structure, potentially enhancing shareholder value and reflecting confidence in the company’s financial health. The transaction adjusts the company’s share capital, affecting the number of shares with voting rights, which stakeholders should note for regulatory compliance.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Executive/Board ChangesRegulatory Filings and Compliance
Haleon PLC Discloses Executive Shareholding Details
Neutral
Jun 3, 2025

Haleon PLC announced a notification regarding the shareholding of Ed Petter, Chief Corporate Affairs Officer, who received the first tranche of Haleon Ordinary Shares under the company’s Share Value Plan. This award was part of his remuneration package to compensate for incentives forfeited from his previous employment, and it is subject to malus and clawback provisions. This transaction reflects Haleon’s adherence to UK Market Abuse Regulations and highlights the company’s commitment to transparent executive compensation practices.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Positive
Jun 3, 2025

Haleon PLC announced the purchase of 794,623 ordinary shares for cancellation as part of its share buyback program initiated in March 2025. This transaction reflects Haleon’s strategic focus on optimizing its capital structure and potentially enhancing shareholder value by reducing the number of shares with voting rights, which now stands at 9,000,455,357.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Regulatory Filings and Compliance
Haleon PLC Updates Total Voting Rights and Share Capital
Neutral
Jun 2, 2025

Haleon PLC announced that as of May 31, 2025, it has issued a total of 9,005,330,185 ordinary shares, with 4,080,205 held as treasury shares. This results in 9,001,249,980 shares having voting rights, a figure crucial for shareholders and others with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules. This update is significant for stakeholders as it impacts the calculation of their interests in the company.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Strengthen Market Position
Positive
Jun 2, 2025

Haleon PLC announced the purchase of 797,519 ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction reflects the company’s strategic financial management, potentially enhancing shareholder value and consolidating its market position by reducing the number of shares with voting rights to 9,001,249,980.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Neutral
May 23, 2025

Haleon PLC announced the purchase of 802,236 ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction, aimed at optimizing the company’s capital structure, reduces the number of shares with voting rights to 9,005,256,948, potentially impacting shareholder interests and market positioning.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Strengthen Market Position
Positive
May 22, 2025

Haleon PLC announced the purchase and cancellation of 810,332 ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction is part of Haleon’s strategy to manage its share capital and potentially enhance shareholder value, reflecting its commitment to maintaining a strong market position.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Strengthen Capital Structure
Positive
May 21, 2025

Haleon PLC announced the purchase and cancellation of 816,897 ordinary shares as part of its share buyback program, which was initiated on March 28, 2025. This transaction is part of a strategic move to optimize the company’s capital structure, potentially enhancing shareholder value and reflecting confidence in its long-term growth prospects.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Neutral
May 20, 2025

Haleon PLC announced the purchase of 820,774 ordinary shares as part of its share buyback program, which was initially announced on March 28, 2025. This transaction is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value. Following this purchase, Haleon’s registered share capital consists of over 9 billion ordinary shares, with a significant portion held as treasury shares, impacting the number of shares with voting rights.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Regulatory Filings and Compliance
Haleon PLC Announces Director Share Purchase
Positive
May 19, 2025

Haleon PLC announced a notification regarding a transaction by a person discharging managerial responsibilities. Bláthnaid Bergin, an Independent Non-Executive Director, purchased 6,145 ordinary shares at £4.0427 each on 16 May 2025, as per the UK Market Abuse Regulation disclosure requirements. This transaction could indicate confidence in the company’s future performance and may impact stakeholder perceptions positively.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Strengthen Market Position
Positive
May 19, 2025

Haleon PLC has announced the purchase of 825,666 ordinary shares for cancellation as part of its share buyback program initiated in March 2025. This transaction reflects the company’s strategic move to optimize its capital structure, potentially enhancing shareholder value and maintaining a robust market position. The updated share capital now stands at 9,012,587,392 ordinary shares, with 9,008,507,187 shares possessing voting rights.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Neutral
May 16, 2025

Haleon PLC announced the purchase and cancellation of 840,928 ordinary shares as part of its share buyback programme. This move is part of a strategic effort to manage its capital structure and potentially enhance shareholder value. Following this transaction, Haleon’s registered share capital consists of over 9 billion ordinary shares, with a significant portion held as treasury shares. This adjustment in share capital may influence shareholder voting rights and interests under regulatory guidelines.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock Buyback
Haleon PLC Executes Share Buyback, Adjusts Share Capital
Neutral
May 15, 2025

Haleon PLC announced the purchase of 835,518 of its own ordinary shares as part of its share buyback program, which was initially announced in March 2025. This transaction reduces the number of shares with voting rights to 9,010,173,781, potentially impacting shareholder interests and market dynamics.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £4.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Optimizes Capital Structure with Share Buyback
Positive
May 14, 2025

Haleon PLC has announced the purchase and cancellation of 820,380 ordinary shares as part of its ongoing share buyback program. This move is aimed at optimizing its capital structure, potentially enhancing shareholder value by reducing the number of shares with voting rights to 9,011,009,299. The transaction reflects Haleon’s strategic financial management and commitment to maintaining a robust market position.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Executive/Board ChangesRegulatory Filings and Compliance
Haleon PLC Announces Executive Share Transactions
Positive
May 13, 2025

Haleon PLC announced the acquisition of Partnership Shares and the award of Matching Shares under its Share Reward Plan by two of its senior executives, Adrian Morris and Tamara Rogers. This notification, in compliance with the UK Market Abuse Regulation, highlights the company’s commitment to aligning managerial interests with shareholder value, potentially strengthening its market position and stakeholder confidence.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Other
Haleon PLC Director Acquires Shares, Signaling Confidence in Market Position
Positive
May 13, 2025

Haleon PLC announced a transaction involving Marie-Anne Aymerich, an Independent Non-Executive Director, who purchased 21,300 ordinary shares at £4.051 each on the London Stock Exchange. This transaction highlights the confidence of the company’s leadership in Haleon’s market position and future prospects, potentially impacting stakeholder perceptions positively.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Positive
May 13, 2025

Haleon PLC announced the purchase of 814,534 ordinary shares for cancellation as part of its share buyback program. This move is part of the company’s strategy to manage its share capital and potentially enhance shareholder value, impacting the number of shares with voting rights and aligning with regulatory requirements.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Neutral
May 12, 2025

Haleon PLC announced the purchase and cancellation of 830,397 ordinary shares as part of its ongoing share buyback programme. This move is part of the company’s strategy to manage its share capital and potentially enhance shareholder value by reducing the number of shares in circulation, which may impact voting rights and shareholding notifications under regulatory guidelines.

Stock BuybackRegulatory Filings and Compliance
Haleon PLC Executes Share Buyback, Adjusts Share Capital
Neutral
May 9, 2025

Haleon PLC announced the purchase and cancellation of 830,504 ordinary shares as part of its share buyback program initiated in March 2025. This transaction adjusts the company’s registered share capital and the number of shares with voting rights, impacting shareholder notifications under regulatory guidelines.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Enhance Shareholder Value
Positive
May 8, 2025

Haleon PLC announced the purchase and cancellation of 828,853 ordinary shares as part of its ongoing share buyback program. This transaction reflects the company’s strategic financial management, potentially enhancing shareholder value and adjusting its capital structure. The update on the company’s share capital and voting rights is crucial for stakeholders to assess their interests in accordance with regulatory requirements.

Private Placements and FinancingRegulatory Filings and Compliance
Haleon PLC Publishes Listing Particulars for £10 Billion EMTN Programme
Neutral
May 7, 2025

Haleon PLC has announced the publication of listing particulars for its £10 billion Euro Medium Term Note Programme, which is guaranteed by the company. This routine update is significant as it underscores Haleon’s commitment to maintaining transparency and accessibility for its investors, potentially impacting its financial strategy and market perception.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Positive
May 7, 2025

Haleon PLC announced the purchase and cancellation of 832,200 ordinary shares as part of its share buyback program. This move is part of a strategic effort to manage its share capital and potentially enhance shareholder value by reducing the number of shares in circulation, thereby increasing the value of remaining shares.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Positive
May 6, 2025

Haleon PLC announced the repurchase of 85,611 of its ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction reflects the company’s strategic effort to manage its capital structure and enhance shareholder value, with implications for voting rights and shareholder notifications under regulatory guidelines.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Positive
Apr 23, 2025

Haleon PLC announced the repurchase of 846,782 ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction is intended to optimize the company’s capital structure and enhance shareholder value. Following this purchase, Haleon’s registered share capital consists of 9,026,151,961 ordinary shares, with 9,022,071,756 shares carrying voting rights. This strategic move is expected to strengthen Haleon’s market position and potentially impact stakeholder interests by adjusting the company’s shareholding structure.

Stock BuybackRegulatory Filings and Compliance
Haleon PLC Executes Share Buyback, Adjusts Share Capital
Neutral
Apr 22, 2025

Haleon PLC announced the purchase and cancellation of 846,648 ordinary shares as part of its share buyback program initiated in March 2025. This transaction adjusts the company’s share capital and affects the number of shares with voting rights, which stakeholders can use to assess their interests under regulatory guidelines.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Positive
Apr 16, 2025

Haleon PLC announced the purchase of 855,279 ordinary shares for cancellation as part of its share buyback program. This transaction, which was executed at a volume-weighted average price of 379.18 pence per share, is part of a strategic move to optimize the company’s capital structure and potentially enhance shareholder value. Following this transaction, the company’s registered share capital stands at 9,028,701,792 ordinary shares, with 9,024,621,587 shares holding voting rights, which may impact shareholder notifications under regulatory guidelines.

Private Placements and FinancingM&A Transactions
Haleon to Fully Acquire Chinese Joint Venture TSKF
Neutral
Apr 15, 2025

Haleon PLC has announced its agreement to acquire the remaining 12% equity interest in its Chinese joint venture, Tianjin TSKF Pharmaceutical Co., Ltd., making it a wholly owned subsidiary. This acquisition, valued at approximately £0.2 billion, is expected to be funded through existing cash resources and new Renminbi-denominated debt, with the transaction anticipated to close within three months, pending customary approvals.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback as Part of Capital Management Strategy
Positive
Apr 15, 2025

Haleon PLC announced the purchase of 865,652 ordinary shares as part of its share buyback program, which was initiated on March 28, 2025. This transaction is part of Haleon’s strategy to manage its capital structure and enhance shareholder value, reflecting confidence in the company’s financial health and future prospects.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Neutral
Apr 14, 2025

Haleon PLC announced the purchase of 887,346 ordinary shares for cancellation as part of its share buyback programme, impacting its share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure and could influence shareholder decisions under regulatory guidelines.

Stock BuybackBusiness Operations and Strategy
Haleon PLC Executes Share Buyback to Optimize Capital Structure
Positive
Apr 7, 2025

Haleon PLC announced the purchase of 821,144 ordinary shares for cancellation as part of its share buyback program. This transaction is part of Haleon’s strategy to manage its share capital and potentially enhance shareholder value. The company’s registered share capital now stands at 9,034,845,270 ordinary shares, with 9,030,765,065 shares having voting rights. This move reflects Haleon’s ongoing efforts to optimize its financial structure and could have implications for its market positioning and shareholder engagement.

Stock Buyback
Haleon PLC Executes Share Buyback Programme
Neutral
Apr 3, 2025

Haleon PLC announced the purchase of 826,862 ordinary shares for cancellation as part of its share buyback programme initiated on 28 March 2025. This transaction impacts the company’s share capital, reducing the number of ordinary shares with voting rights to 9,032,421,345, which stakeholders can use to assess their interests under the FCA’s Disclosure Guidance and Transparency Rules.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 24, 2025